Invo BioScience EPS - Earnings per Share 2010-2024 | NAYA
Invo BioScience eps - earnings per share from 2010 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Invo BioScience Annual EPS |
| 2023 |
$-5.13 |
| 2022 |
$-17.97 |
| 2021 |
$-12.60 |
| 2020 |
$-30.40 |
| 2019 |
$-9.00 |
| 2018 |
$-12.80 |
| 2017 |
$0.00 |
| 2016 |
$-12.80 |
| 2015 |
$-25.60 |
| 2014 |
$-12.80 |
| 2013 |
$-6.40 |
| 2012 |
$-6.40 |
| 2011 |
$-6.40 |
| 2010 |
$-15.36 |
| 2009 |
$-54.40 |
| Invo BioScience Quarterly EPS |
| 2024-06-30 |
$-0.62 |
| 2024-03-31 |
$-0.42 |
| 2023-12-31 |
$2.73 |
| 2023-09-30 |
$-0.70 |
| 2023-06-30 |
$-3.06 |
| 2023-03-31 |
$-4.10 |
| 2022-12-31 |
$-4.56 |
| 2022-09-30 |
$-4.19 |
| 2022-06-30 |
$-4.62 |
| 2022-03-31 |
$-4.60 |
| 2021-12-31 |
$0.60 |
| 2021-09-30 |
$-4.80 |
| 2021-06-30 |
$-3.40 |
| 2021-03-31 |
$-5.00 |
| 2020-12-31 |
$-12.00 |
| 2020-09-30 |
$-7.20 |
| 2020-06-30 |
$-5.40 |
| 2020-03-31 |
$-5.80 |
| 2019-12-31 |
$-5.04 |
| 2019-09-30 |
$-3.00 |
| 2019-06-30 |
$-0.96 |
| 2019-03-31 |
$0.00 |
| 2018-12-31 |
$-5.75 |
| 2018-09-30 |
$0.00 |
| 2018-06-30 |
$-6.40 |
| 2018-03-31 |
$-0.65 |
| 2017-12-31 |
$0.00 |
| 2017-09-30 |
$0.00 |
| 2017-06-30 |
$0.00 |
| 2017-03-31 |
$0.00 |
| 2016-12-31 |
$-6.40 |
| 2016-09-30 |
$0.00 |
| 2016-06-30 |
$-6.40 |
| 2016-03-31 |
$0.00 |
| 2015-12-31 |
$0.00 |
| 2015-09-30 |
$0.00 |
| 2015-06-30 |
$-25.60 |
| 2015-03-31 |
$0.00 |
| 2011-12-31 |
$-1.28 |
| 2011-09-30 |
$-0.64 |
| 2011-06-30 |
$-2.56 |
| 2011-03-31 |
$-1.92 |
| 2010-12-31 |
$-17.92 |
| 2010-09-30 |
$-2.56 |
| 2010-06-30 |
$-3.84 |
| 2010-03-31 |
$8.96 |
| 2009-12-31 |
$-1.28 |
| 2009-09-30 |
$-40.32 |
| 2009-06-30 |
$-5.12 |
| 2009-03-31 |
$-7.68 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.004B |
$0.003B |
|
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
|
